Cystic fibrosis (CF) is a life-shortening disease caused by the mutations that generate non-functional CF transmembrane conductance regulator (CFTR) protein. A rare serine-to-tyrosine (S1045Y) CFTR mutation was earlier reported to result in CF-associated fatality. We identified an African American patient with the S1045Y mutation in CFTR, as well as a stop-codon mutation, who has a mild CF phenotype. The underlying mechanism of CF caused by S1045Y-CFTR has not been elucidated. In this study, we determined that S1045Y-CFTR exhibits two-fold attenuated function compared to WT-CFTR.
Introduction
Approximately one in every 3500 children born in the United States inherits cystic fibrosis (CF) (7) .
Although CF affects multiple-organs, most debilitating symptoms occur in the lung with recurrent episodes of bacterial infections and perpetual decline in lung function (6, 21, 26) . CF develops due to biallelic inheritance of loss-of-function mutations in the gene encoding for the CF transmembrane conductance regulator (CFTR) membrane protein. To date, approximately 2000 mutations have been identified in the cftr gene (http://www.genet.sickkids.on.ca/cftr). The CFTR protein is a member of the ATP-binding cassette (ABC) transporter family that actively transports chloride ions (Cl -) into the lumen when stimulated by cyclic nucleotides (cAMP or cGMP) and this, together with sodium ions, drives the osmotic flow of water (2, 9, 12, 13) . Defect in CFTR synthesis or function perturb the water-driving force and the epithelial surfaces lining the lung, gastrointestinal tract, and pancreas become dehydrated, resulting in the mucus secretions becoming sticky and building up on these epithelial surfaces. This defect manifests as defective mucociliary clearance in the lungs with 100% penetrance in CF, meconium ileus (obstructed gut) in the gut in 10% of CF infants, and pancreatic insufficiency in 80-90% of the CF patient population (25) . CF-causing CFTR mutations are broadly categorized into five classes depending upon the spectra of causes that affect synthesis and/or function (28) . Class I CFTR mutations (e.g., G542X) lead to severed protein synthesis due to the presence of a premature stop codon and Class II mutations (e.g., the most common CF causing mutation, ∆F508) has folding or maturation defects, both of which can result in premature CFTR degradation, while Class III mutations (e.g., G551D) cause defective gating and inability to pump chloride ions in response to cAMP, Class IV mutations (e.g., R117H) affect chloride conductance due to defects in the channel pore, and Class V mutations (e.g., 3849+10KbC>T) change code for splice mutants, leading to an overall reduction in normal CFTR synthesis (22) . On the basis of molecular defects, mutations in Classes I-III would cause more severe phenotypic consequences (22, 28) . Conversely, Class IV and V mutants may have residual CFTR function, thus leading to a milder CF phenotype. Additional defect (Class VI) in CFTR function is related to poor retention of the protein at the plasma membrane connected to multiple factors, such as for rescued F508del-CFTR mutant emanating from thermodynamic and kinetic destabilization of NBD1 with the mutation, misfoldingdriven internalization, and poor abilities to engage in protein-protein interactions (4, 10, 19, 24) .
Surprisingly, CFTR trafficked normally to the plasma membrane can become rapidly endocytosed (5-10% per minute) (24) . A tyrosine-based (YXXϕ) internalization motif 1424 YDSI in CFTR is conserved across species and mediates CFTR endocytosis by adaptor protein complex-2 (AP-2) clathrin-mediated mechanisms (1, 18) . Recent findings imply that ubiquitin can play a major role in regulating the fate of membrane proteins (17, 24) . Membrane surface receptors such as epidermal growth factor receptor (EGFR) may be decorated with poly-or mono-ubiquitin, with the former driving to proteasomal degradation and the latter directing it to lysosomal degradation (8, 11, 23) . E3 ubiquitin ligase Casitas Blineage lymphoma proto-oncogene (c-cbl) is an important player in tagging receptor tyrosine kinases with ubiquitin, including activated/phosphorylated EGFR, facilitating its recruitment into lysosomes (23) . The association of c-cbl with EGFR and subsequent ubiquitination likely occurs at the plasma membrane prior to internalization, but it seems to function as a sorting signal for an endocytic fate post internalization, and c-cbl remains associated with EGFR throughout the endocytic pathway until the final fate is decided (11).
c-cbl harbors a tyrosine kinase binding (TKB) domain and binds EGFR in its activated state (pY1045 EGFR). It has been suggested that c-cbl binds wild-type (WT)-CFTR, labeling it with ubiquitin in endosomes and channeling it to lysosomes for degradation (27) . By reducing c-cbl expression, an increase in CFTR-mediated Cl -currents was observed (27) . The same group demonstrated that c-cbl can affect ∆F508 CFTR surface expression (5). The consensus binding site for c-cbl is (D/E)XpYXXXφ (where φ is a hydrophobic amino acid; usually proline).
We identified an African American patient with mild CF phenotype carrying two CFTR mutations:
c.2885C>A (p.Ser926X) and c.3134C>A (p.Ser1045Tyr). To determine the molecular mechanism rendering S1045Y CFTR mutation as pro-CF, we studied the flanking sequence surrounding the tyrosine mutation and determined that the serine (Ser)-to-tyrosine (Tyr) alteration at position 1045 changes the context of the sequence into a putative c-cbl binding site. We hypothesized that the mutant protein might therefore acquire the fate of activated EGFR upon tyrosine phosphorylation and becomes a c-cbl target, leading to ubiquitination and a major proportion of the tyrosine-phosphorylated CFTR ultimately residing in endosomes/lysosomes.
Results

Homozygous state of S1045Y CFTR can cause CF
It is important for this study that we establish the clinical basis of investigating S1045Y-CFTR mutation.
We identified an individual who is a carrier of S1045Y, with the mutation in the second allele causing a synthesis block in CFTR, and who suffers from mild CF. Individuals who carry ∆F508-CFTR with one normal copy of CFTR are CF asymptomatic, and there needs to be two defective copies of that mutant CFTR protein to inherit CF. This supports that the S1045Y mutation in CFTR can potentially lead to certain CFTR-associated defects. A S1045Y mutation in CFTR on both alleles was previously reported in a Galician female who had confirmed CF (20) . Therefore, S1045Y-CFTR could cause severe CF in its homozygous state. We present here a previously undocumented brief clinical summary of a S1045Y-CFTR carrier with mild CF.
Case summary ( (Fig. 1) .
Previous studies estimate that correction of the CF phenotype requires restoration of mutant CFTR function to 25-35% of the WT-CFTR activity (1, 15) . Since this patient had a stop codon mutation, which encodes a truncated CFTR protein, and the S1045Ymutation with a CF phenotype, and due to a prior study reporting that an individual homozygous for S1045Y had severe CF disease (20) , we conducted biochemical studies to unveil the molecular characteristics of S1045Y-CFTR.
S1045Y-CFTR exhibits a 50% reduction in channel function compared to WT-CFTR
To study the molecular profile of S1045Y-CFTR, we used site-directed mutagenesis to generate a Ser-toTyr mutation at position 1045 in CFTR protein using WT-CFTR as a template ( Fig. 2A) . Stable HEK 293 cell lines carrying FLAG-WT-CFTR or FLAG-S1045Y-CFTR were generated and tested for CFTR protein expression and channel function. S1045Y-CFTR protein was expressed similarly as WT-CFTR, with normal Band C and B configurations, suggesting that S1045Y-CFTR traffics properly to the plasma membrane (Fig. 2B) . Functional analysis of CFTR revealed a 50% reduction of function with the S1045Y mutation compared to WT-CFTR using an iodide efflux assay (Fig. 2C) . We also generated CFBEo -cells carrying the S1045Y mutation ( Fig. 2D ) and monitored CFTR channel function in polarized cells mounted in an Ussing chamber, which is a more physiologically relevant system to study CFTR function.
We observed a 50% reduction in the function of S1045Y-CFTR compared to WT-CFTR.
S1045Y-CFTR exhibits accelerated internalization compared to WT-CFTR
Due to the introduction of a Tyr residue in the S1045Y mutation and the role of Tyr-based endocytic motifs, we were interested in determining whether this mutation would alter the rate of internalization of the mutant protein. Using CFTR-specific immunostaining, we observed a significant intracellular presence of S1045Y-CFTR compared to WT-CFTR (Fig. 3A) . This provided a first indication of S0145Y-CFTR being unable to remain at the cell surface as well as WT-CFTR. To further validate this observation, we used a cleavable cell-permeant EZ-Link-Sulfo-NHS-S-S-Biotin to label surface proteins including CFTR, and follow their endocytic fate. In this assay, cells labeled and maintained on ice are at a state of no endocytosis, which would determine the total amount of labeled surface CFTR for normalizing the endocytosed protein. Separately, cells labeled with this biotin on ice are switched to 37ºC to trigger endocytosis and followed for 5 min. Cells are then switched back to 4ºC, and biotin is reductively cleaved from the remaining surface proteins. We observed that the surface levels of S1045Y-CFTR are two-fold lower compared to WT-CFTR and approximately 47% of S1045Y-CFTR was internalized in 5 min compared to ~10% for WT-CFTR (Fig. 3B) . Thus, the Tyr mutation at 1045 predisposes CFTR to rapid endocytosis.
After we determined that S1045Y-CFTR is synthesized normally, traffics properly to the membrane, but becomes rapidly endocytosed, we further explored the molecular changes that would trigger this process.
We found that the introduction of Tyr turns the sequence context into a putative binding site of the E3 ubiquitin ligase c-cbl (KQLEpYEGRSP) in its phosphorylated state. We therefore hypothesized that a phosphorylation event could render S1045Y-CFTR endocytic and it may not be typical of the C-terminal
Tyr motif-based endocytosis of CFTR. We used H 2 O 2 (10 µM)/Vanadate (0.02-1 mM) to accumulate Tyr phosphorylation in HEK 293 cells overexpressing FLAG-tagged WT-CFTR and S1045Y-CFTR. To test whether the Tyr mutation becomes phosphorylated in S1045Y-CFTR, we immunoprecipitated FLAG-tagged WT-and S1045Y-CFTR proteins from cells with or without H 2 O 2 /Vanadate treatment using FLAG-antibodyconjugated resin. The immunoprecipitated proteins (CFTR-enriched) were probed with HRP-conjugated phosphotyrosine antibody. We observed that S1045Y-CFTR exhibited three-to four-fold enhanced
Tyrosine phosphorylation corresponding to 1045Y compared to WT-CFTR with H 2 O 2 /Vanadate challenge ( Fig. 3C) . To determine whether enhanced tyrosine phosphorylation of S1045Y-CFTR predisposes the protein to a rapid endocytic process, we utilized a surface biotinylation assay. HEK 293 cells overexpressing FLAG-tagged WT-CFTR or S1045Y-CFTR were subjected to 15-min and 60-min treatments with H 2 O 2 /Vanadate at 37ºC and subsequently labeled with cell impermeable biotinylating reagent NHS-LC-Biotin. We observed that a 15-min Tyr phosphorylation trigger reduced S1045Y-CFTR surface levels by 40% and only 10% of S1045Y-CFTR remained at the surface after 60 min of the treatment. The surface levels of WT-CFTR remained intact under these treatment conditions (Fig. 3D) .
Thus, Tyr phosphorylation is a trigger for rapid internalization of S1045Y-CFTR.
Inhibition of Tyr phosphorylation enhances surface levels of S1045Y-CFTR and improves its function
The pivotal component of the study would be determination of the specific tyrosine kinase that associates with the mutant protein. Through initial screening attempts with several tyrosine kinases, we narrowed it down to Janus kinase 1 (JAK1) as the tyrosine-kinase binding partner of CFTR that preferentially associates with S1045Y-CFTR protein (Fig. 4A) . Since Tyr phosphorylation of S1045Y-CFTR is the molecular trigger for its rapid internalization, we sought to determine whether inhibition of Tyr phosphorylation can prevent S1045Y-CFTR internalization. We used a surface-labeling assay to determine surface levels of CFTR. HEK 293 cells expressing WT-or S1045Y-CFTR were treated with the protein synthesis inhibitor cycloheximide (CHX; 100 µg/ml) for 3-4 h to allow selective study of the CFTR population present at the plasma membrane. Following CHX chase, cells were treated with various tyrosine-kinase inhibitors: ruxolitinib 5 µM (selective JAK1/2 inhibitor), lapatinib 0.5 µM (EGFR and ErbB2 inhibitor), or genistein 50 µM [generic protein tyrosine kinase (PTK) inhibitor] for 60 min at 37ºC
with no-treatment controls in parallel. We observed that all of the tyrosine-kinase inhibitors could marginally rescue S1045Y-CFTR level, but that there are no such effects observed for WT-CFTR (Fig.   4B ). To functionally demonstrate the partial restoration of the S1045Y-associated defect, we mounted CFBEo -cells in Ussing Chambers and studied CFTR chloride-channel function for S1045Y-CFTRexpressing cells pretreated with tyrosine-kinase inhibitors (genistein 50 µM, lapatinib 0.5 µM, imatinib 0.5 µM and ruxolitinib 10 µM) in response to forskolin (10 μM). We observed partial rescue (15-186% increase) of S1045Y-CFTR function most effectively with genistein ( Fig. 4C) . Since JAK1 inhibition could not completely rescue S1045Y-CFTR surface levels to WT-CFTR surface amounts, we predict that JAK1 is not the sole tyrosine kinase to preferentially interact with S1045Y-CFTR and that multiple kinases could be associated with the mutant protein.
Tyr phosphorylation in S1045Y-CFTR promotes docking of E3 ubiquitin ligase c-cbl on the mutant protein
Since we hypothesized a gain of site of Tyr phosphorylation in the mutant protein, and subsequent binding of c-cbl we tested whether S1045Y-CFTR would exhibit enhanced binding to c-cbl compared to WT-CFTR and whether a Tyr phosphorylation stimulus would enhance such binding. In our initial experiments, we observed a very weak and almost undetectable binding of c-cbl with S1045Y-CFTR.
Therefore, we cross-linked the protein complexes to capture the interaction. FLAG-tagged WT-or S1045Y-CFTR proteins not subjected or subjected to H 2 O 2 /Vanadate treatment for 60 min were cross-linked with the cell-permeable cross-linker dithiobis succinimidyl propionate (DSP; 1 mM) at 37 ºC. We observed c-cbl co-immunoprecipitating with CFTR only under an oxidative condition, and S1045Y-CFTR exhibited increased binding with c-cbl compared to WT-CFTR (Fig. 5A) . Since we established that c-cbl recognizes S1045Y-CFTR in its phosphorylated state, we next tested whether S1045Y-CFTR is more ubiquitinated than WT-CFTR. Western-blot analysis using ubiquitin-specific antibody of immunoprecipitated WT-and S0145Y-CFTR proteins revealed that S1045Y-CFTR exhibits more ubiquitination compared to WT-CFTR (Fig. 5B) . Next, we attempted to address the specificity of ubiquitination of S1045Y-CFTR through c-cbl. Toward this end, we knocked down c-cbl expression levels using c-cbl-directed Stealth RNAi™ siRNA. We then checked the surface levels of WT-and S1045Y-CFTR upon downregulation of c-cbl expression using surface-labeling assay. Interestingly, we did not observe any rescue of the surface levels of S1045Y-CFTR with c-cbl downregulation and observed a slight decrease instead (Fig. 5C ). This data suggests that the ubiquitinating event through c-cbl
is not critical for S1045Y-CFTR endocytosis and that Tyr phosphorylation drives this process. A marginal decrease in the surface levels of S1045Y CFTR upon c-cbl knock-down is suggestive of the role of ubiquitination of internalized protein pool in regulating the rate of internalization of the membrane protein.
Based on this data, we predict that c-cbl-mediated ubiquitination would be important to promote lysosomal degradation of the mutant protein.
To support this notion and establish c-cbl specificity toward ubiquitinating S1045Y-CFTR and facilitate its lysosomal recruitment, we evaluated total protein levels (cytoplasmic + membrane) and observed an increase in the total pool of S1045Y-CFTR upon c-cbl downregulation, with no such change observed in WT-CFTR amounts (Fig. 5D) . Therefore, c-cblmediated ubiquitination regulates post-internalization fate of S1045Y-CFTR.
Discussion
In this study, we elucidated the molecular basis of how the S1045Y mutation in CFTR can cause CF (Fig.   6 ). We demonstrated that (1) S1045Y-CFTR retains only 50% of normal CFTR activity in its homozygous form under a steady state condition and hence, ~25% when the heterozygote provided the other allele to encode a non-functional CFTR, such as in the case we present that the second mutation is a stop mutation. We would anticipate the patient to be on the borderline of 25% CFTR function, which explains his mild-CF manifestations; (2) Tyr phosphorylation of the mutant protein is the molecular trigger for enhanced internalization of the protein and therefore, the state of Tyr phosphorylation in a given cell would determine the functional profile of the mutant protein and could be predicted to be lower than 50% of normal CFTR activity, and (3) We speculate that the S1045Y-CFTR protein is monoubiquitinated rather than polyubiquitinated, as the latter would target the protein for proteosomal degradation and we did not observe an increase in the levels of S1045Y-CFTR protein levels with MG-132, an inhibitor of proteosomal degradation (data not shown). Information on the fate of monoubiquitinated CFTR is currently limited. However, misfolding of CFTR within the cytosolic domains has been demonstrated to be a potent signal for attachment of ubiquitin chains and driving the protein into degradative pathways (14) . We do not think that misfolding is a possibility for the enhanced ubiquitination of S1045Y-CFTR, since it exhibited levels of mature Band C comparable to that of WT-CFTR. Consequently, S1045Y-CFTR is a strong candidate for a distinct monoubiquitination event.
Although a rare mutation, one individual homozygous for S1045Y-CFTR did have severe life-shortening lung involvement (20) . This Galician female suffered from acute pancreatitis, allergic bronchopulmonary aspergillosis, and had chronic pulmonary symptoms (dyspnea, productive cough, nasal congestion, and diffuse bronchiectasis). She had clearly elevated sweat chloride levels (>90 MEq/L) and later acquired respiratory infections with Pseudomonas aeruginosa and Morganella morganii. Copious and thick mucus secretions were found at bronchoscopy, particularly in the upper lobe. The patient died with renal failure and progressive respiratory and haemodynamic deterioration. Our S1045Y CFTR carrier patient has so far had a milder CF disease course, but he is currently being followed for development of pulmonary complications. Since the residual function of S1045Y CFTR would vary depending upon the oxidative state of the cell, it would be important to prevent oxidative stress in S1045Y CFTR patients. We identified JAK1 as a tyrosine kinase to demonstrate selective binding towards the mutant protein.
Since we observed only a marginal improvement in S1045Y-CFTR function with a JAK1 inhibitor, there could be redundancy in Tyr phosphorylation of the mutant protein or additive action by several other tyrosine kinases. Genistein could act through dual mechanisms to benefit S1045Y-CFTR function by partially rescuing surface levels of S1045Y-CFTR and by potentiating CFTR function. Consequently we observed more potent improvement in the function of S1045Y-CFTR in I sc measurements using genistein compared to other tyrosine-kinase inhibitors. Soybeans and soy food (e.g., tofu, soy flour, soy milk) are enriched in isoflavones (genistein is an isoflavones derivative) and are consumed in significant amounts in Asian countries and also becoming popular in Western countries. Soy products are inexpensive and high in quality protein. Genistein constitutes 53% of total isoflavones in soy flour (3). Based on our in vitro data, we speculate that a soy diet and other isoflavones could benefit S1045Y patients by inhibiting Tyr phosphorylation, providing a unique personalized therapy for this rare CFTR mutation.
Materials and methods
Patient studies
Patient studies were approved under IRB no. 13-02779-XM.
Generation of the S1045Y CFTR mutant
Ser to Tyr mutation was generated using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) to convert cytosine 3134 to adenine 3134 (c.3134C>A) and using FLAG-WT-CFTR cDNA as a template. Stable cells expressing FLAG-WT and FLAG-S1045Y-CFTR were generated by transducing HEK 293 and CFBEo -cells with the lentiviral particles carrying WT-CFTR and S1045Y-CFTR, with subsequent selection of positive clones on 10µg/ml puromycin for one week and maintenance on 2µg/ml puromycin.
Reagents
Tyrosine-kinase inhibitors ruxolitinib, lapatinib, and imatinib were purchased from Selleck Chem, Houston, TX. Cycloheximide (CHX) and genistein were obtained from Sigma-Aldrich, St. Louis, MO.
Forskolin was purchased from Tocris Bioscience, Bio-Techne, Minneapolis, MN. To check for tyrosine-phosphorylated proteins, HEK 293 cells grown to confluence in 60 mm dishes were treated with 100 µM H 2 O 2 and 2 mM sodium orthovanadate for 15 min at 37°C and lysed and immunopreciptated with FLAG beads. CFTR purified on the FLAG beads was glycine eluted and probed with pY HRP antibody (Thermo Scientific) prepared in 5% BSA TBS-Tween.
Immunoblotting
Immunofluorescence
HEK 293 cells expressing WT-or S1045Y-CFTR protein grown to 50% confluence were washed with PBS twice and fixed in 4% paraformaldehyde for 15 min, followed by a permeabilization step using PBS 0.3% Triton-X-100 for 15 min. Cells were then blocked in 4% BSA PBS-Tween for 2 h at room temperature (RT) and incubated with rabbit R3194 CFTR antibody (1:100) overnight at 4⁰C. After incubation, cells were washed three times with PBS 0.05% Tween (5 min each wash). Alexa-fluor 488 rabbit secondary antibody (1:500) was added to the cells for 1 h, and cells were washed three times with PBS 0.05% Tween (5 min each wash). In the final step, cells were mounted in Vectashield fluorescence mounting media containing DAPI. Images were captured using an Olympus FV1200 confocal microscope.
CFTR endocytosis assay
HEK 293 cells expressing WT-or S1045Y-CFTR protein were grown in 60 mm dishes to confluence.
Cells were washed two times with prewarmed PBS pH 7.4 containing Ca 2+ and Mg 2+ and subsequently washed one time with ice-cold PBS pH 8.0 without Ca 2+ and Mg 2+ . Washed cells were incubated with 1 mg/ml cell-permeant EZ-Link-Sulfo-NHS-S-S-Biotin (Thermo Scientific) with a cleavable disulphide bond prepared in PBS pH 8.0 to label the surface proteins, including CFTR, on ice to prevent any endocytosis at this stage. A set of dishes were maintained on ice, therefore corresponding to no endocytosis, to determine the total amount of labeled surface CFTR and normalize the endocytosed protein. Separately, cells labeled with biotin kept on ice were switched to 37ºC to trigger endocytosis and followed for 5 min. Later, these cells were switched back to 4ºC and biotin was reductively cleaved from the remaining surface proteins by incubating the cells twice for 15 min with stripping buffer pH 8.6 [100 mM 2-ercaptoethanesulfonic acid (MESNA), 50 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.2% BSA] with no shaking. Cells were subsequently rinsed one time with PBS 1% BSA and incubated on ice for 15 min.
Next, cells were lysed in NP-40 lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1 % NP-40). After measuring protein concentrations and normalizing the protein amounts for each sample, 30 µl streptavidin-conjugated resin was added to each sample and allowed to mix overnight at 4⁰C. After incubation, samples were washed three times with the NP-40 lysis buffer and eluted in 5X sample buffer.
Samples were run on 8% polyacrylamide gels and immunoblotted with mouse monoclonal M3A7 CFTR antibody. Levels of CFTR protein were calculated as mean gray value using ImageJ.
Biotinylation of surface CFTR
HEK 293 cells expressing WT-or S1045Y-CFTR protein were grown in 60 mm dishes. To monitor the effect of tyrosine phosphorylation on CFTR endocytosis, cells were subjected to 10 µM 
Iodide efflux assay
HEK 293 cells stably expressing WT-CFTR and S1045Y-CFTR were grown on poly-L-lysine coated 60-mm dishes to 100% confluence. Briefly, cells were loaded for 60 min at RT with loading buffer (136 mM NaI prepared in the buffer with the following composition: 137 mM NaCl, 4.5 mM KH 2 PO4, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 5 mM HEPES, pH 7.2). Extracellular NaI was washed away thoroughly (5-7 times) with efflux buffer (136 mM NaNO 3 prepared in the buffer as mentioned before replacing 136 mM NaI in the loading buffer) and then, cells were equilibrated for 1 min each and aliquots collected for four times to establish a stable base line in the efflux buffer alone. After establishing basal equilibrium with the nitrate buffer, cells were treated with CFTR-agonists (forskolin 10 µM and 100 µM IBMX) prepared in the nitrate buffer, and aliquots were collected for six times at 1-min intervals. The iodide concentration of each aliquot collected was determined using an iodide-sensitive electrode (Thermo Scientific) and converted to iodide content (nanomoles/min) as described previously (16).
Short-circuit current (I sc ) measurements
Polarized CFBEo -monolayers were grown on Costar Transwell permeable supports (Cambridge, MA; filter diameter 6.5 mm) until the monolayers reached both confluency and transepithelial resistance > 800
Ω. The transwells were subsequently mounted in an Ussing chamber maintained at 37°C. I sc was measured as described previously (9 To test the effect of tyrosine-kinase inhibitors on S1045Y-CFTR function, S1045Y-CFTR-expressing CFBEo -cells were preincubated with 50 µM genistein and 0.5 µM lapatinib for 15 min prior to addition of CFTR agonists. At the end of every I sc measurement, CFTR inhibitor (CFTR inh -172; 20-50 μM) was added to the apical side at the end of the experiment to verify that the I sc were CFTR-dependent.
Surface-labeling assay
HEK 293 cells expressing FLAG-WT-CFTR, S1045Y-CFTR were grown in poly-L-lysine-coated 12-well plates until 100% confluent. In an initial step, cells were incubated with 100 µg/ml CHX for 3 h at 37°C to eliminate any contribution from newly synthesized protein. Afterward, tyrsoine-kinase inhibitors were added and cells were incubated for 60 min at 37°C. Cells were then washed, fixed with 3.7% formaldehyde for 10 min, blocked with 1% BSA for 90 min, and treated with α-FLAG HRP (0.2 μg/ml) for 90 min. The HRP substrate 1-Step Ultra TMB (Pierce, Waltham, MA) was then added to the dishes and observed for color intensity. The reaction was stopped by adding an equal amount of 2 N H 2 SO 4 and absorbance was read at 450 nm.
Statistical Analysis
Results are presented as mean ± SEM for the indicated number of experiments. Statistical analysis was performed using Student's t-test. A value of P < 0.05 was considered statistically significant. 
(B)
Western-blot to test CFTR ubiquitination levels showing enhanced ubiquitination of S1045Y-CFTR protein compared to WT-CFTR protein.
(C)
Surface-labeling assay to determine the surface FLAG-WT-CFTR and FLAG-S1045Y-CFTR levels upon knockdown of c-cbl expression using Stealth siRNA. Scr siRNA: scrambled siRNA was used as a non-specific knockdown control.
(D)
Western-blot to determine total WT and S1045Y CFTR levels with and without c-cbl knockdown.
Figure 6.
Molecular machinery that assembles on S1045Y CFTR protein and causes it to loose surface retention and function by 50%. 
